TIF
An educational leaflet aiming to strengthen the knowledge and understanding of patients with thalassaemia and other haemoglobin disorders across the world on most aspects relevant to gene therapy.
Latest News:
- TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
- New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019
- Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
- US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
- New CRISPR editing tool could potentially fix 89% of genetic variations in human diseases
